Pre-analytical and analytical aspects affecting clinical reliability of plasma glucose results

Clinical Biochemistry

Volumn 50, Issue 10-11, 2017, Pages 587-594

  Pasqualetti, Sara ^a   Braga, Federica ^a   Panteghini, Mauro ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Analytical performance specifications; EQAS; Glucose; Standardization; Uncertainty

Indexed keywords

CITRIC ACID; GLUCOSE; GLUCOSE BLOOD LEVEL;

CLINICAL LABORATORY; GLUCOSE ASSAY; GLUCOSE BLOOD LEVEL; HOSPITAL PATIENT; HUMAN; MEASUREMENT; POINT OF CARE TESTING; PRIORITY JOURNAL; RELIABILITY; REVIEW; STANDARDIZATION; UNCERTAINTY; ANALYSIS; BLOOD ANALYSIS; BLOOD SAMPLING; CHEMISTRY; GLYCOLYSIS; PROCEDURES; STANDARDS;

BLOOD CHEMICAL ANALYSIS; BLOOD GLUCOSE; BLOOD SPECIMEN COLLECTION; CITRIC ACID; GLYCOLYSIS; HUMANS;

EID: 85015990943     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2017.03.009     Document Type: Review

References (90)

1. World Health Organization. Global Reports on Diabetes 2016. ISBN 978 92 4 156525 7 (NLM classification: WK 810). http://apps.who.int/iris/bitstream/10665/204871/1/9789241565257_eng.pdf (accessed 31.01.17).
2. International Diabetes Federation, IDF Diabetes Atlas 7th Edition. http://www.oedg.at/pdf/1606_IDF_Atlas_2015_UK.pdf, 2015 (accessed 31.01.17).
3. American Diabetes Association, Standards of medical care in diabetes 2016. Diabetes Care 39:Suppl. 1 (2016), S1–S112.
4. Fraser, C.G., Biological Variation: from Principles to Practice. 2001, AACC Press, Washington, DC, 9–18.
5. Lippi, G., Banfi, G., Church, S., Cornesa, M., De Carli, G., Grankvista, K., et al. Preanalytical quality improvement. In pursuit of harmony, on behalf of European Federation for Clinical Chemistry and Laboratory Medicine (EFLM) working group for preanalytical phase (WG-PRE). Clin. Chem. Lab. Med. 53 (2015), 357–370.
6. Topic, E., Nikolac, N., Panteghini, M., Theodorsson, E., Salvagno, G.L., Miler, M., et al. How to assess the quality of your analytical method?. Clin. Chem. Lab. Med. 53 (2015), 1707–1718.
7. Panteghini, M., Application of traceability concepts to analytical quality control may reconcile total error with uncertainty of measurement. Clin. Chem. Lab. Med. 48 (2010), 7–10.
8. Chan, A.Y.W., Swaminanthan, R., Cockram, C.S., Effectiveness of sodium fluoride as a preservative of glucose in blood. Clin. Chem. 35 (1989), 315–317.
9. Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycemia: Report of a WHO/IDF Consultation. 2006, WHO Press ISBN 978 92 4 159493 6.
10. Sacks, D.B., Arnold, M., Bakris, G.L., Bruns, D.E., Horvath, A.R., Kirkman, M.S., et al., National Academy of Clinical Biochemistry; Evidence-Based Laboratory Medicine Committee of the American Association for Clinical Chemistry, Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin. Chem. 57 (2011), e1–e47.
11. Stapleton, M., Daly, N., O'Kelly, R., Turner, M.J., Time and temperature affect glycolysis in blood samples regardless of fluoride-based preservatives: a potential underestimation of diabetes. Ann. Clin. Biochem., 2017, 10.1177/0004563216682978 (Epub ahead of print). Jan 1:4563216682978.
12. Sacks, D.E., Bruns, D.E., Goldstein, D.E., Maclaren, N.K., McDonald, J.M., Parrott, M., Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin. Chem. 48 (2002), 436–472.
13. Mikesh, L.M., Bruns, D.E., Stabilization of glucose in blood specimens: mechanism of delay in fluoride inhibition of glycolysis. Clin. Chem. 54 (2008), 930–932.
14. Uchida, K., Matuse, R., Toyoda, E., Okuda, S., Tomita, S., A new method of inhibiting glycolysis in blood samples. Clin. Chim. Acta 172 (1988), 101–108.
15. Uchida, K., Okuda, S., Tanaka, K., Inventors, Terumo Corporation, assignee, Method of inhibiting glycolysis in blood samples. US Patent 4,780,419, 1988 Oct 4.
16. Bruns, D.E., Knowler, W.C., Stabilization of glucose in blood samples: why it matters. Clin. Chem. 55 (2009), 850–852.
17. Gambino, R., Piscitelli, J., Ackattupathil, T.A., Theriault, J.L., Andrin, R.D., Sanfilippo, M.L., et al. Acidification of blood is superior to sodium fluoride alone as an inhibitor of glycolysis. Clin. Chem. 55 (2009), 1019–1021.
18. Bonetti, G., Cancelli, V., Coccoli, G., Piccinelli, G., Brugnoni, D., Caimi, L., et al. Which sample tube should be used for routine glucose determination?. Prim. Care Diabetes 10 (2016), 227–232.
19. Peake, M.J., Bruns, D.E., Sacks, D.B., Horvath, A.R., It's time for a better blood collection tube to improve the reliability of glucose results. Diabetes Care, 36, 2013, e2.
20. del Pino, I.G., Constanso, I., Mourín, L.V., Safont, C.B., Vázquez, P.R., Citric/citrate buffer: an effective antiglycolytic agent. Clin. Chem. Lab. Med. 51 (2013), 1943–1949.
21. Szőke, D., Valente, C., Panteghini, M., Better blood collection tubes for plasma glucose: ready for prime time?. Clin. Chem. Lab. Med., 52, 2014 e87-e9.
22. van den Berg, S.A., Thelen, M.H., Salden, L.P., van Thiel, S.W., Boonen, K.J., It takes acid, rather than ice, to freeze glucose. Sci. Rep., 5, 2015, 8875.
23. Bonetti, G., Carta, M., Montagnana, M., Lo Cascio, C., Bonfigli, A.R., Mosca, A., et al. Italian joint SIBioC-SIPMeL study group on diabetes mellitus. Effectiveness of citrate buffer-fluoride mixture in Terumo tubes as an inhibitor of in vitro glycolysis. Biochem. Med. 26 (2016), 68–76.
24. Dimeski, G., Yow, K.S., Brown, N.N., Evaluation of the accuracy of the Greiner bio-one FC mix glucose tube. Clin. Chem. Lab. Med., 2016 Sep 22. pii: /j/cclm.ahead-of-print/cclm-2016-0611/cclm-2016-0611.xml. (Epub ahead of print).
25. Dimeski, G., Yow, K.S., Brown, N.N., What is the most suitable blood collection tube for glucose estimation?. Ann. Clin. Biochem. 52 (2014), 270–275.
26. Juricic, G., Kopcinovic, L.M., Saracevic, A., Bakliza, A., Simundic, A.M., Liquid citrate acidification introduces significant glucose bias and leads to misclassification of patients with diabetes. Clin. Chem. Lab. Med. 54 (2016), 363–371.
27. Juricic, G., Bakliza, A., Saracevic, A., Kopcinovic, L.M., Dobrijevic, S., Drmic, S., et al. Glucose is stable during prolonged storage in un-centrifuged Greiner tubes with liquid citrate buffer, but not in serum and NaF/KOx tubes. Clin. Chem. Lab. Med. 54 (2016), 411–418.
28. Carta, M., Montagnana, M., Cascio, C.L., Bonetti, G., Italian joint SIBioC-SIPMeL study group on diabetes mellitus. Glucose sampling: importance of citrate. Ann. Clin. Biochem. 53 (2016), 715–716.
29. Bakliza, A., Juricic, G., Saracevic, A., Milevoj Kopcinovic, L., Simundic, A.M., New tubes on the block: ready for a better blood collection tubes for plasma glucose. Clin. Chem. Lab. Med., 53, 2015, eA226.
30. Pasqualetti, S., Szőke, D., Birindelli, S., Dolci, A., Panteghini, M., Optimal collection tubes for plasma glucose determination: confusion reigns supreme. Clin. Chem. Lab. Med. 54 (2016), e281–e283.
31. Juricic, G., Saracevic, A., Kopcinovic, L.M., Bakliza, A., Simundic, A.M., The evidence for clinically significant bias in plasma glucose between liquid and lyophilized citrate buffer additive. Clin. Biochem. 49 (2016), 1402–1405.
32. van der Hagen, E.A.E., Kleefman, A.D.M., Thelen, M.H.M., van den Berg, S.A.A., Normalization issues in glucose measurements using phlebotomy tubes with liquid additives. Clin. Chem. Lab. Med. 55 (2017), e1–e3.
33. Szőke, D., Valente, C., Pasqualetti, S., Panteghini, M., Glycolysis inhibition and reliable plasma glucose results: is the clinical impact carefully considered?. Biochim. Clin. 39 (2015), 76–77.
34. Pasqualetti, S., Szőke, D., Valente, C., Panteghini, M., Glycolysis inhibition and reliable plasma glucose results: is the clinical impact carefully considered?. Clin. Chem. Lab. Med., 53, 2015, S104.
35. Ridefelt, P., Åkerfeldt, T., Helmersson-Karlqvist, J., Increased plasma glucose levels after change of recommendation from NaF to citrate blood collection tubes. Clin. Biochem. 47 (2014), 625–628.
36. Norman, M., Jones, I., The shift from fluoride/oxalate to acid citrate/fluoride blood collection tubes for glucose testing - the impact upon patient results. Clin. Biochem. 47 (2014), 683–685.
37. Gambino, R., Sodium fluoride: an ineffective inhibitor of glycolysis. Ann. Clin. Biochem. 50 (2013), 3–5.
38. Pasqualetti, S., Panteghini, M., Clinical impact of glycolysis inhibition on plasma glucose results requires caution. Ann. Clin. Biochem. 54 (2017), 302–303.
39. Fraser, C.G., Harris, E.K., Generation and application of data on biological variation in clinical chemistry. Crit. Rev. Clin. Lab. Sci. 27 (1989), 409–437.
40. Panteghini, M., The future of laboratory medicine: understanding the new pressures. Clin. Biochem. Rev. 25 (2004), 207–216.
41. Fraser, C.G., Kallner, A., Kenny, D., Petersen, P.H., Introduction: strategies to set global quality specifications in laboratory medicine. Scand. J. Clin. Lab. Invest. 59 (1999), 477–478.
42. Braga, F., Panteghini, M., Generation of data on within-subject biological variation in laboratory medicine: an update. Crit. Rev. Clin. Lab. Sci. 53 (2016), 313–325.
43. Bartlett, W.A., Braga, F., Carobene, A., Coşkun, A., Prusa, R., Fernandez-Calle, P., et al. A checklist for critical appraisal of studies of biological variation. Clin. Chem. Lab. Med. 53 (2015), 879–885.
44. Desirable Specifications for Total Error, Imprecision, and Bias, Derived from Intra- and Inter-Individual Biologic Variation. http\\www.westgard.com\biodatabase1.htm (accessed 02.01.17).
45. Pineda-Tenor, D., Laserna-Mendieta, E.J., Timón-Zapata, J., Rodelgo-Jiménez, L., Ramos-Corral, R., Recio-Montealegre, A., et al. Biological variation and reference change values of common clinical chemistry and haematologic laboratory analytes in the elderly population. Clin. Chem. Lab. Med. 51 (2013), 851–862.
46. Costongs, G.M., Janson, P.C., Bas, B.M., Hermans, J., van Wersch, J.W., Brombacher, P.J., Short-term and long-term intra-individual variations and critical differences of clinical chemical laboratory parameters. J. Clin. Chem. Clin. Biochem. 23 (1985), 7–16.
47. Young, D.S., Harris, E.K., Cotlove, E., Biological and analytic components of variation in long-term studies of serum constituents in normal subjects. IV. Results of a study designed to eliminate long-term analytic deviations. Clin. Chem. 17 (1971), 403–410.
48. Loh, T.P., Metz, M.P., Indirect estimation of pediatric between-individual biological variation data for 22 common serum biochemistries. Am. J. Clin. Pathol. 143 (2015), 683–693.
49. Fraser, C.G., Improved monitoring of differences in serial laboratory results. Clin. Chem. 57 (2011), 1635–1637.
50. Ollerton, R.L., Playle, R., Ahmed, K., Dunstan, F.D., Luzio, S.D., Owens, D.R., Day-to-day variability of fasting plasma glucose in newly diagnosed type 2 diabetic subjects. Diabetes Care 22 (1999), 394–398.
51. Carlsen, S., Petersen, P.H., Skeie, S., Skadberg, Ø., Sandberg, S., Within-subject biological variation of glucose and HbA1c in healthy persons and in type 1 diabetes patients. Clin. Chem. Lab. Med. 49 (2011), 1501–1507.
52. Aloisio, E., Frusciante, E., Dolci, A., Panteghini, M., Verifica dell'accuratezza di tre glucometri “point-of-care” per l'utilizzo in ambito ospedaliero. Biochim. Clin., 41, 2017 article in press.
53. Braga, F., Dolci, A., Montagnana, M., Pagani, F., Paleari, R., Guidi, G.C., et al. Revaluation of biological variation of glycated hemoglobin (HbA1c) using an accurately designed protocol and an assay traceable to the IFCC reference system. Clin. Chim. Acta 412 (2011), 1412–1416.
54. Panteghini, M., Sandberg, S., Defining analytical performance specifications 15 years after the Stockholm conference. Clin. Chem. Lab. Med. 53 (2015), 829–832.
55. Sandberg, S., Fraser, C.G., Horvath, A.R., Jansen, R., Jones, G., Oosterhuis, W., et al. Defining analytical performance specifications: consensus statement from the 1st strategic conference of the European Federation of Clinical Chemistry and Laboratory Medicine. Clin. Chem. Lab. Med. 53 (2015), 833–835.
56. Ceriotti, F., Fernandez-Calle, P., Klee, G.G., Nordin, G., Sandberg, S., Streichert, T., et al. Criteria for assigning laboratory measurands to models for analytical performance specifications defined in the 1st EFLM strategic conference. Clin. Chem. Lab. Med. 55 (2017), 189–194.
57. Horvath, A.R., Bossuyt, P.M., Sandberg, S., John, A. St, Monaghan, P.J., Verhagen-Kamerbeek, W.I., et al., Test Evaluation Working Group of the European Federation of Clinical Chemistry and Laboratory Medicine, Setting analytical performance specifications based on outcome studies – is it possible?. Clin. Chem. Lab. Med. 53 (2015), 841–848.
58. Hyltoft Petersen, P., Brandslund, I., Jørgensen, L.G., Stahl, M., de Fine Olivarius, N., Borch-Johnsen, K., Evaluation of systematic and random factors in measurements of FPG as the basis for analytical quality specifications in the diagnosis of diabetes. 3. Impact of the new WHO and ADA recommendations on diagnosis of diabetes mellitus. Scand. J. Clin. Lab. Invest. 61 (2001), 191–204.
59. Hyltoft Petersen, P., Jørgensen, L.G., Brandslund, I., de Fine Olivarius, N., Stahl, M., Consequences of bias and imprecision in measurements of glucose and HbA1c for the diagnosis and prognosis of diabetes mellitus. Scand. J. Clin. Lab. Invest. 65:Suppl. 240 (2005), 51–60.
60. Knowler, W.C., Fowler, S.E., Hamman, R.F., Christophi, C.A., Hoffman, H.J., Brenneman, A.T., et al., Diabetes Prevention Program Research Group, 10-year follow-up of diabetes incidence and weight loss in the diabetes prevention program outcomes study. Lancet 374 (2009), 1677–1686.
61. Paulweber, B., Valensi, P., Lindstrom, J., Lalic, N.M., Greaves, C.J., McKee, M., et al. A European evidence-based guideline for the prevention of type 2 diabetes. Horm. Metab. Res. 42:Suppl. 1 (2010), S3–S36.
62. Fraser, C.G., Hyltoft Petersen, P., Libeer, J.C., Ricos, C., Proposals for setting generally applicable quality goals solely based on biology. Ann. Clin. Biochem. 34 (1997), 8–12.
63. van den Berg, S.A., Thelen, M.H., Tiel Groenestege, W.M., Intra-laboratory variation and its effect on gestational diabetes diagnosis. Clin. Chem. Lab. Med., 2017, 10.1515/cclm-2016-0979 (Epub ahead of print). Feb 15. pii: /j/cclm.ahead-of-print/cclm-2016-0979/cclm-2016-0979.xml.
64. Panteghini, M., Traceability as a unique tool to improve standardization in laboratory medicine. Clin. Biochem. 42 (2009), 236–240.
65. Braga, F., Panteghini, M., Verification of in vitro medical diagnostics (IVD) metrological traceability: responsibilities and strategies. Clin. Chim. Acta 432 (2014), 55–61.
66. Theodorsson, E., Magnusson, B., Leito, I., Bias in clinical chemistry. Bioanalysis 6 (2014), 2855–2875.
67. JCGM 200, International Vocabulary of Metrology (VIM) - Basic and General Concepts and Associated Terms. third ed., 2012.
68. Braga, F., Panteghini, M., Metrological traceability as a tool to standardize measurements in laboratory medicine. Biochim. Clin. 39 (2015), 551–558.
69. Bais, R., Armbruster, D., Jansen, R.T., Klee, G., Panteghini, M., Passarelli, J., et al. Defining acceptable limits for the metrological traceability of specific measurands. Clin. Chem. Lab. Med. 51 (2013), 973–979.
70. Braga, F., Infusino, I., Panteghini, M., Performance criteria for combined uncertainty budget in the implementation of metrological traceability. Clin. Chem. Lab. Med. 53 (2015), 905–912.
71. Panteghini, M., Implementation of standardization in clinical practice: not always an easy task. Clin. Chem. Lab. Med. 50 (2012), 1237–1241.
72. Braga, F., Infusino, I., Panteghini, M., Role and responsibilities of laboratory medicine specialists in the verification of metrological traceability of in vitro medical diagnostics. J. Med. Biochem. 34 (2015), 282–287.
73. Ceriotti, F., The role of external quality assessment schemes in monitoring and improving the standardization process. Clin. Chim. Acta 432 (2014), 77–81.
74. Ferraro, S., Braga, F., Panteghini, M., Laboratory medicine in the new healthcare environment. Clin. Chem. Lab. Med. 54 (2016), 523–533.
75. Miller, W.G., Jones, G.R., Horowitz, G.L., Weykamp, C., Proficiency testing/external quality assessment: current challenges and future directions. Clin. Chem. 57 (2011), 1670–1680.
76. Infusino, I., Frusciante, E., Braga, F., Panteghini, M., Progress and impact of enzyme measurement standardization. Clin. Chem. Lab. Med. 55 (2017), 334–340.
77. Carobene, A., Ceriotti, F., Infusino, I., Frusciante, E., Panteghini, M., Evaluation of the impact of standardization process on the quality of serum creatinine determination in Italian laboratories. Clin. Chim. Acta 427 (2014), 100–106.
78. Mosca, A., Paleari, R., Carobene, A., Weykamp, C., Ceriotti, F., Performance of glycated hemoglobin (HbA1c) methods evaluated with EQAS studies using fresh blood samples: still space for improvements. Clin. Chim. Acta 451 (2015), 305–309.
79. Braga, F., Frusciante, E., Infusino, I., Aloisio, E., Guerra, E., Ceriotti, F., et al. Evaluation of the trueness of serum alkaline phosphatase measurement in a group of Italian laboratories. Clin. Chem. Lab. Med. 55 (2017), e47–e50.
80. Thelen, M.H., Jansen, R.T., Weykamp, C.W., Steigstra, H., Meijer, R., Cobbaert, C.M., Expressing analytical performance from multi-sample evaluation in laboratory EQA. Clin. Chem. Lab. Med., 2017, 10.1515/cclm-2016-0970 (Epub ahead of print). Feb 9. pii: /j/cclm.ahead-of-print/cclm-2016-0970/cclm-2016-0970.xml.
81. Jansen, R., Jassam, N., Thomas, A., Perich, C., Fernandez-Calle, P., Faria, A.P., et al. A category 1 EQA scheme for comparison of laboratory performance and method performance: an international pilot study in the framework of the calibration 2000 project. Clin. Chim. Acta 432 (2014), 90–98.
82. Xia, C., Liu, O., Wang, L., Xu, G., Trueness assessment for serum glucose measurement using commercial systems through the preparation of commutable reference materials. Ann. Lab. Med. 32 (2012), 243–249.
83. Weykamp, C., Secchiero, S., Plebani, M., Thelen, M., Cobbaert, C., Thomas, A., et al. Analytical performance of 17 general chemistry analytes across countries and across manufacturers in the INPUtS project of EQA organizers in Italy, the Netherlands, Portugal, United Kingdom and Spain. Clin. Chem. Lab. Med. 55 (2017), 203–211.
84. Rajendran, R., Rayman, G., Point-of-care blood glucose testing for diabetes care in hospitalized patients: an evidence-based review. J. Diabetes Sci. Technol. 8 (2014), 1081–1090.
85. ISO 15197:2013(E), In Vitro Diagnostic Test Systems – Requirements for Blood Glucose Monitoring Systems for Self-Testing in Managing Diabetes Mellitus. 2013, International Organization for Standardization, Geneva, Switzerland.
86. CLSI, Point-of-Care Blood Glucose Testing in Acute and Chronic Care Facilities; Approved Guideline - 3rd ed. CLSI document POCT12-A3. 2013, Wayne, PA, Clinical and Laboratory Standards Institute.
87. Blood Glucose Monitoring Test Systems for Prescription Point-of-Care Use, Draft Guidance for Industry and Food and Drug Administration Staff. www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm380325.pdf (accessed 02.01.17).
88. Parkes, J.L., Slatin, S.L., Pardo, S., Ginsberg, B.H., A new consensus error grid to evaluate the clinical significance of inaccuracy in the measurement of blood glucose. Diabetes Care 23 (2000), 1143–1148.
89. Krouwer, J.S., Why specifications for allowable glucose meter errors should include 100% of the data. Clin. Chem. Lab. Med. 51 (2013), 1543–1544.
90. Gambino, R., Glucose: a simple molecule that is not simple to quantify. Clin. Chem. 53 (2007), 2040–2041.